Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research CommunicationsGlobe Newswire • 30 days ago
TPST-1120, a first-in-class, oral, selective PPAR antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data...
Share to Feed
Tempest Therapeutics, Inc. (NASDAQ:TPST Free Report) HC Wainwright issued their Q1 2024 earnings estimates for Tempest Therapeutics in a report released on Wednesday, March 20th...
Tempest Therapeutics (NASDAQ:TPST Get Free Report)s stock had its buy rating restated by HC Wainwright in a research report issued to clients and investors on Wednesday...
Tempest Therapeutics (NASDAQ:TPST Get Free Report)s stock had its outperform rating restated by investment analysts at William Blair in a note issued to investors on...
Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in two...
Glancy Prongay & Murray LLP (GPM) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors and officers possible violations of state laws. If...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...